Vincent Giacalone, DPM
Foot & Ankle Surgery · Emerson, NJNPI 1285637025
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,416 of the $73,633 with a category attached, or 75.3%. Paratek Pharmaceuticals, Inc. accounts for 68.1% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $39,079, more than ten times the $447 reported in 2019. Among foot & ankle surgery clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $277.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$50K
- Organogenesis Inc.$16K
- Orpyx Medical Technologies Inc.$2K
- Smith+Nephew$1K
- Tactile Systems Technology Inc$661
- Kerecis Limited$527
- plus $3K from 31 others
Across 77 payments — averaging $996.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotissue Holdings Inc.$60K
- Royal Biologics, Inc.$15K
- Regeneron$2K
What the payments were for
- Consulting fees$2,0003%
- Speaking & faculty fees$55,41675%
- Travel & lodging$6,0658%
- Food & beverage$9,93413%
- Education$2180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 95 | $50,125 |
| Organogenesis Inc. | 41 | $15,679 |
| Orpyx Medical Technologies Inc. | 1 | $2,000 |
| Smith+Nephew | 39 | $1,384 |
| Tactile Systems Technology Inc | 12 | $661 |
| Kerecis Limited | 4 | $527 |
| Integra Lifesciences Corporation | 11 | $480 |
| Stryker | 5 | $397 |
| Treace Medical Concepts, Inc. | 7 | $361 |
| Urgo Medical North America, LLC | 4 | $226 |
| DJO, LLC | 2 | $218 |
| Averitas Pharma Inc. | 4 | $201 |
| GRT US Holding, Inc. | 3 | $152 |
| Amgen | 3 | $152 |
| Abbott | 1 | $140 |
| Nevro Corp. | 1 | $135 |
| Endo USA, Inc. | 1 | $80 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $73 |
| Zimmer Biomet | 2 | $68 |
| Boston Scientific | 1 | $63 |
| AbbVie | 4 | $55 |
| Vaporox, Inc. | 1 | $47 |
| Orthofix Medical, Inc. | 2 | $45 |
| Next Science LLC | 1 | $42 |
| Convatec Inc. | 2 | $38 |
| Fidia Pharma USA Inc. | 1 | $35 |
| Medtronic | 2 | $35 |
| Inari Medical, Inc. | 1 | $34 |
| Cardiovascular Systems Inc. | 1 | $31 |
| Resmed Corp | 1 | $30 |
| Zimvie Inc. | 1 | $29 |
| KCI USA, Inc. | 1 | $18 |
| Hydrofera LLC | 1 | $18 |
| Hartmann USA, Inc. | 1 | $17 |
| Orpyx Medical Technologies US Inc. | 1 | $16 |
| Paragon 28, Inc. | 1 | $12 |
| Cashflow Solutions, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$48,873
- Puraply Antimicrobial$5,876
- PURAPLY WOUND MATRIX$4,081
- Apligraf$3,728
- Affinity$3,598
- NOVACHOR$1,979
- NuShield$1,979
- PuraPly$1,500
- Kerecis Omega3 Marigen$917
- INTEGRA$734
- Kerecis Omega3 SurgiClose$705
- Kerecis SurgiClose$591
- Flexitouch Plus$521
- Nimbl$382
- Qutenza$274
- INTEGRA DERMAL REGENERATION TEMPLATE$245
- PRIMATRIX$245
- REGRANEX$238
- Lapiplasty System$238
- DR COMFORT$218
How this compares
$73,633 in reported general payments places this provider in the 95th percentile of 542 foot & ankle surgery providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 26 | $13,125 |
| Cromolyn Sodium | 11 | $2,129 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 23 | $403 |
| Methylprednisolone | 19 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,384 | $13,12526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 foot & ankle surgery providers in New Jersey.
Other foot & ankle surgery in Emerson
- John CozzarelliBelleville$932K
- Matthew RegulskiToms River$843K
- Michael SubikLyndhurst$529K
- Krupa PatelMorris Plains$281K
- Johanna GodoyWayne$254K
- Andrew BriefRidgewood$253K
- Mark SolomonCedar Knolls$232K
- Evan AdlerOld Bridge$195K
- Shane HollawellManasquan$169K
- Jacob ReinkrautRidgewood$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.